Fair Value Distribution — percentile bands
100.0% of simulations place fair value above current price
WHAT IS PRICED IN
FCF-Based Reverse DCF
8.3%/yr
±3.4% · FCF growth to justify current price
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Cardinal Health, Inc.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
CAH reports strong Q2 (19% rev growth, margin expansion), driven by MSO platform acquisitions and pharma sales. However, rising leverage (B debt, 3.6x estimated net leverage), tariff headwinds, and MS...